By Michael Dabaie
Schrodinger Inc. said it is in a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-electron microscopy in connection with in silico compound screening to accelerate drug discovery.
The collaboration uses Schrodinger's software platform with Thermo Fisher's cryo-EM technology to expand the applicability of structure-based drug discovery to a wider array of targets. Schrodinger provides a computational platform to accelerate drug discovery and materials design.
Schrodinger said it will identify drug discovery targets and Thermo Fisher will obtain cryo-EM structures of these targets. Schrodinger said it will then use its computational platform to identify development candidates.
Schrodinger shares were up 3% to $78.00 in premarket trading. Thermo Fisher was up 1.3% to $356.63.
Write to Michael Dabaie at firstname.lastname@example.org